Jan Kehler

This inventor holds 65 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 28 EPO patents, primarily in PDE1 Inhibitors (CPC class C07D). Top assignees: H. Lundbeck A/s, Other. Active years: 2005-2023.

USPTO Granted Patents = 65 (Patent Applications = 5)

% Patents Active = 33.8

CIPO Patents = 4 (Patent Applications = 9)

EPO Patents = 28 (Patent Applications = 28)

Average Co-Inventor Count = 4.2

ph-index = 7

Forward Citations = 136(Granted Patents)

Forward Citations (Not Self Cited) = 25(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Kgs. Lyngby, DK (2005 - 2014)
Valby, DK (2018 - 2021)
Lyngby, DK (2007 - 2023)

Company Filing History:

64 out of 511

H. Lundbeck A/s

patents

1 out of 834,307

Other

patents

Years Active: 2005-2023

Loading Chart...

Areas of Expertise:

PDE1 Inhibitors

Pyrazolo[4,3-B]pyridines

Imidazopyrazinones

Quinazolin Derivatives

Combination Treatments

Macrocycles

Triazolopyrazinones

Hexahydrofuropyrroles

Phenylimidazole Derivatives

Substituted Imidazoles

Quinoline Derivatives

Heteroaromatic Compounds

65 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11851425 - Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines (2023-12-26),

2. 11634416 - Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines (2023-04-25),

3. 11535611 - Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors (2022-12-27),

4. 11491140 - 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors (2022-11-08),

5. 11472810 - Imidazopyrazinones as PDE1 inhibitors (2022-10-18),

6. 11104680 - 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors (2021-08-31),

7. 11026924 - 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors (2021-06-08),

8. 11026923 - 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors (2021-06-08),

9. 10912773 - Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors (2021-02-09),

10. 10905688 - Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors (2021-02-02),

11. 10858362 - Imidazopyrazinones as PDE1 inhibitors (2020-12-08),

12. 10806718 - 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors (2020-10-20),

13. 10766893 - 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors (2020-09-08),

14. 10689379 - Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors (2020-06-23),

15. 10633382 - Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors (2020-04-28),

Title: Jan Kehler: A Prolific Danish Inventor at the Forefront of Neurodegenerative Treatments

Introduction: Jan Kehler, a distinguished inventor hailing from Lyngby, Denmark, has made significant contributions to the field of healthcare with a remarkable portfolio of 65 patents to his name. His groundbreaking work in the development of combination treatments for neurodegenerative disorders has garnered widespread recognition in the scientific community.

Latest Patents: Jan Kehler's latest patents revolve around the innovative use of 1H-pyrazolo[4,3-b]pyridin-7-amines as PDE1 inhibitors in conjunction with other compounds for the treatment of neurodegenerative and psychiatric disorders. These patents highlight his commitment to advancing treatment options for individuals suffering from cognitive and mental health conditions.

Career Highlights: Throughout his career, Jan Kehler has been affiliated with prominent companies such as H. Lundbeck A/S, where his expertise in inventing novel pharmaceutical compositions has been instrumental in driving forward the boundaries of medical research. His patent portfolio stands as a testament to his unwavering dedication to improving the quality of life for patients worldwide.

Collaborations: Jan Kehler has collaborated closely with esteemed colleagues such as Morten Langgård and Karsten Juhl, whose shared passion for innovation has led to the development of cutting-edge healthcare solutions. Together, they have fostered a culture of creativity and excellence, propelling their inventions to the forefront of the industry.

Conclusion: In conclusion, Jan Kehler's journey as an inventor embodies a commitment to pushing the boundaries of traditional medicine and revolutionizing the treatment landscape for neurodegenerative and psychiatric disorders. His relentless pursuit of innovation serves as an inspiration to aspiring inventors and reaffirms the profound impact that one individual can have on the world of healthcare.